Home » Topics » BioWorld Science

BioWorld Science
RSS

RPR redirects development of PDE IV inhibitor

Nov. 21, 1997

Bayer seeks FDA approval for metrifonate for Alzheimer's disease

Nov. 21, 1997

KeraVision Ring evaluated in extended phase III trial

Nov. 21, 1997

Notice of allowance issued for DepoTech's drug delivery patent

Nov. 21, 1997

Company Profile: Transkaryotic Therapies

Nov. 21, 1997

New NK3/NK4 antagonist in the pipeline at SKB

Nov. 20, 1997

Phase II begins for psoriasis vaccine

Nov. 20, 1997

Phase II results with T-cell receptor peptides in RA promising

Nov. 20, 1997

HMR and MediGene collaborate on cancer gene therapies

Nov. 20, 1997

Extensive preclinical results described for new NK2 antagonist

Nov. 20, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...